A patient enrolled in a phase 1/2a study of OpRegen for dry age-related macular degeneration showed signs of retinal tissue regeneration, according to a press release.
After retinal pigment epithelium cell transplantation with Lineage Cell Therapeutics’ lead product candidate in one patient of 17 so far enrolled, geographic atrophy was 25% smaller at 9 months than at baseline. In the next 6 months, the area grew approximately 50% slower than its historical rate, according to the release.
The data were originally observed by an independent external advisor using multiple imaging
Uncategorized